|
|
||||||||
|
|
|||||||||
|
|
Oncology-Clinical Diagnosis: Solid TumorsClinical Diagnosis-Solid Tumors Posters |
1 Nuclear Medicine, William Beaumont Hospital, Royal Oak, Michigan; 2 Nuclear Medicine, Tri-service General Hospital, Taipei, Taiwan; 3 University of Tennessee, Knoxville, Tennessee
1499
Objectives: To investigate the newly defined time sensitivity (S) of tumor by serial FDG PET.
Methods: Dual time (t) protocol (P) FDG PET scans from 40 pts with pathologically proven head and neck (H&N) tumors without brain metastasis were analyzed. P.I (1.5 & 2-hr): 26 pts (M:F=20:6, age=61±17) with early (E) and delayed (D) PET obtained at 106±15 and 135±16 min after injection of 16.3±1.9 mCi FDG. P.II (1 & 2-hr): 14 pts (M:F=12:2, age=55±12) with E and D PET performed at 54±13 and 151±28 min after injection of 9.6±1.7 mCi FDG. The serum glucose (Glu) was recorded before each scan and the maximum SUV were measured in the primary tumor (CA1) and the cerebellum (CBL). S =d{ln(SUV)}/d{ln(t)} was obtained by linear regression of ln (SUV) vs ln (t). Paired t-tests with p<0.05 was considered significant.
Results: D SUV were significantly higher than E SUV in CA1 for both P.I (18.3±6.9 vs 14.3±5.8, p<0.0005) and P.II (11.5±7.9 vs 9.7±6.9, p=0.013). The S values for CA1 in P.I and P.II were 1.12 and 0.15 respectively. Glu was not significantly different in both P.I and P.II (103±25 vs 93±14, p=ns). The D SUV were also higher than E SUV in CBL for both P.I (12.1±2.2 vs 11.2±2.5, p<0.0005) and P.II (7.6±1.6 vs 7.0±1.6, p=0.008). The S values for CBL in P.I and P.II were 0.39 and 0.017 respectively, which were over 2-fold smaller than that of CA1, suggesting phenotypic differences between CA1 and CBL.
Conclusions: There exists another metabolic phenotype of CA1 besides SUV measured by the newly defined S using serial FDG PET. It offers another useful Dx tool in optimizing choices of dual time protocols and in reducing SUV variations due to time differences.
| ||||||||||||||||||||||||||||||||||||||